Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Abstract

PURPOSE Anecortave acetate is a novel angiostatic cortisene being evaluated clinically for treatment of exudative age-related macular degeneration (ARMD). A randomized, placebo-controlled, efficacy and safety dose duration study of anecortave acetate for depot suspension (3 mg, 15 mg, 30 mg) in this patient population was completed in June 2003. As part of… (More)

Topics

Cite this paper

@article{SchmidtErfurth2005AnecortaveAF, title={Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.}, author={Ursula M Schmidt-Erfurth and Stanton Michels and Rolf H Michels and Annemarie Aue}, journal={European journal of ophthalmology}, year={2005}, volume={15 4}, pages={482-5} }